• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Solaraze (diclofenac sodium) gel 3%

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011


Summary View


Drug Interactions

  • Specific interaction studies between Solaraze® Gel and other topical or oral agents were not performed.


Oral Nonsteroidal Anti-Inflammatory Drugs

  • Although low, there is systemic exposure to diclofenac following labeled use of Solaraze Gel. Therefore, concomitant administration of Solaraze® Gel with oral NSAIDS or aspirin may result in increased NSAID adverse effects.